Eliminating government waste, fraud, abuse, and mismanagement is challenging. Every program receives the taxpayer’s money and support from vested interests, and its existence is rarely tied to results. Congress is supposed to provide oversight and accountability but even when hearings are held, they do not usually lead to the consolidation or elimination of programs. In […]
President Donald Trump has made addressing healthcare costs a priority of his second term in office. While this is a noble goal, it is important that this goal is achieved while rejecting foreign price controls. On September 30, 2026, the Center for Medicare and Medicaid Innovation (CMMI) announced it had finalized the Global Benchmark for […]
Welcome to This Week in Waste, a series by Citizens Against Government Waste (CAGW) that highlights how taxpayer dollars are being wasted in the federal, state, and local levels of government and efforts to fight back against this spendthrift behavior. Senate Health, Education, Labor, and Pensions (HELP) Committee Hearing is Next Step for 340B Reform The […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
Improper payments have long been an avoidable drain on the federal budget and are often prominently featured as an example of wasteful spending. It is therefore not surprising that in the August 12, 2025, Government Accountability Office (GAO) updated report on open recommendations to improve government operations, reducing fraud and improper payments was first on […]
The Inflation Reduction Act creates instability in the Medicare Part D Program.
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
Taxpayers and beneficiaries should be concerned with the Biden administration’s proposed cuts to Medicare Advantage.
IRA drug price controls will devastate future drug development, resulting in more lives lost.
House Democrats’ new bill on price controls will devastate future drug development and raise costs.
